Chemoprevention Trial for Uremia-Associated Urothelial Carcinoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00172367|
Recruitment Status : Withdrawn (This study was for National Science Council project. The study was not funded, so the study was withdrawn.)
First Posted : September 15, 2005
Last Update Posted : September 26, 2008
Primary Objective: To study if lycopene can improve the biomarker status of urothelial cells in patients with uremia-associated urothelial carcinoma.
Secondary Objective: To evaluate the general safety and tolerability of oral lycopene 30 mg per day for 12 weeks in uremic patients.
|Condition or disease||Intervention/treatment||Phase|
|Carcinoma, Transitional Cell||Drug: Lycopene||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||80 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Study Start Date :||January 2006|
- changes of intermediate biomarker status after lycopene supplementation
- safety and tolerability
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00172367
|National Taiwan University Hospital|
|Principal Investigator:||Yeong-Shiau Pu, MD, PhD||National Taiwan University Hospital|